Clinical Trial Update: Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) [Phase 3]

View source ↗

Summary

A Phase III study named Hallmark DUAL evaluated the combination of asunaprevir and daclatasvir for Hepatitis C, with the trial status showing as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• Daclatasvir (daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus | Phase 3 | Status: COMPLETED